The FDA has approved bepirovirsen (Hibsago) for adults with chronic hepatitis B, without cirrhosis, who are taking antiviral therapy. This approval follows findings from the B-Well 1 and B-Well 2 trials. Nearly 1 in 5 patients taking the antisense oligonucleotide drug alongside background antivirals achieved a functional cure, compared to none in a placebo group. The indication stipulates use along with nucleos(t)ide analog reverse transcriptase inhibitor therapy in patients who have taken antiviral therapy for at least 6 months, have suppressed HBV blood levels, and have HBsAg levels of 3,000 IU/mL or less.
In phase III trials, 19-20% of patients with HBsAg levels of 3,000 IU/mL or less achieved a functional cure at week 72. For patients with HBsAg levels of 1,000 IU/mL – approximately 45% of diagnosed cases worldwide – the functional cure rate reached 26%. Bepirovirsen is administered as a 6-month course and can be self-administered after the initial dose.
The treatment approach offers the possibility of maintaining virus control after chronic HBV treatment ends. Wendy Carter, DO, of FDA’s Center for Drug Evaluation and Research stated this approval represents an important advance for people living with this serious disease. Common side effects include injection site reactions, fatigue, fever, and headache. The approved prescribing information includes boxed warnings regarding serious hepatic flares and low platelet counts, which can cause life-threatening thrombocytopenia. Other warnings include risks of worsening kidney function, serious inflammatory adverse reactions such as vasculitis, and serious risks from improper injection. Regular blood tests are required for patients using bepirovirsen. Bepirovirsen is not recommended in patients with hepatitis D virus coinfection.